People with HCV Archives – Page 2 of 3

A Partnership to Expand Access to Lifesaving Testing and Treatment for Hepatitis C

September 20, 2021
Dorrit Walsh

Hepatitis C PACT was launched in 2021 and aims to tackle ongoing disparities in access to diagnostics and treatment for hepatitis C virus (HCV) in low-and middle-income countries (LMICs), home to 75% of people living with the viral illness. This brief explains the group's goals and work.

Cover of the brief: Hepatitis C and COVID-19 Global Concerns: Sustained Financing and Expanded Access to Testing and Pangenotypic Treatments Needed to Recover the Path to Elimination

Hepatitis C and COVID-19 Global Concerns: Sustained Financing and Expanded Access to Testing and Pangenotypic Treatments Needed to Recover the Path to Elimination

February 1, 2021
Dorrit Walsh

This policy brief highlights strategies that leverage the COVID-19 response towards improving access to HCV diagnostics, treatment, and care.

New York Increases Access to Hepatitis C Treatment for Medicaid Patients

September 21, 2020
Dorrit Walsh

The National Viral Hepatitis Roundtable (NVHR), the Center for Health Law and Policy Innovation of Harvard Law School (CHLPI), and the Treatment Action Group (TAG) today applauded New York State (NYS) Medicaid for removing the requirement that new patients receive prior authorization approval for hepatitis C treatment.

Fair Pricing for Cepheid Xpert Tests (COVID-19, HIV, TB, HCV)

April 3, 2020
Dorrit Walsh

On Friday, April 3, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF), and the Global Coalition of TB Activists (GCTA) held a webinar on the price of Xpert tests for COVID-19, TB, HIV, HCV and other diseases.

African Declaration to Eliminate Hepatitis C and Improve the Health of People Who Use Drugs

February 20, 2020
Dorrit Walsh

A group of organizations that includes Treatment Action Group issued this statement/declaration today, while attending INHSU 2020 Africa: the 1st Regional Conference on Hepatitis Care in Substance Users.

Responding to Difficult-to-Treat HCV Subtypes Prevalent in Sub-Saharan Africa

February 17, 2020
Dorrit Walsh

An issue brief that discusses the recent discovery of HCV subtypes that show resistance to direct-acting antiretroviral (DAA) regimens that are responsive to treatments in people expressing the 1a/1b subtype.

Good COPs or Bad COPs: Promoting Interventions for Coinfections and AIDS in 2020 PEPFAR Country Operational Plans (COPs)

January 22, 2020
Dorrit Walsh

On January 22, 2020, Treatment Action Group (TAG), Médecins Sans Frontières (MSF) Access Campaign, Health GAP, IMPAACT4TB, and AVAC presented this webinar on how to engage in PEPFAR COPs advocacy. Materials are online now.

Activist Guide to Hepatitis C Virus Diagnostics

October 31, 2019
Chad Cipiti

The purpose of this new publication is to provide information for you and your community. The Activist Guide aims to provide a deeper focus on diagnosis with updated information about the steps and different technologies involved in diagnosing a person with hepatitis C.

HCV Genotypes

February 6, 2017
Chad Cipiti

February 2017 What are genotypes? A genotype is a way to put the hepatitis C virus (HCV) into categories based on similar genes. It’s important to know and understand HCV genotypes because different genotypes respond differently to medicines that treat…

Viekira XR and Technivie Fact Sheet

February 2, 2017
Chad Cipiti

Updated February 2017 The goal of hepatitis C virus (HCV) treatment is a cure (when there is no HCV in a person’s bloodstream at least 12 weeks after treatment is finished). What is Viekira XR? Viekira XR is a combination…